Author

Arjun D. Koch

Established vs. rising techniques - Expert Exchange (PENTAX Europe GmbH)
Established vs. rising techniques - Expert Exchange (PENTAX Europe GmbH)

Arjun D. Koch  et al.

LOW RISK OF LOCAL RECURRENCE AFTER A SUCCESSFUL EN BLOC ENDOSCOPIC SUBMUCOSAL DISSECTION FOR COLORECTAL LESIONS WITH A POSITIVE HORIZONTAL RESECTION MARGIN (R-ESD STUDY)
LOW RISK OF LOCAL RECURRENCE AFTER A SUCCESSFUL EN BLOC ENDOSCOPIC SUBMUCOSAL DISSECTION FOR COLORECTAL LESIONS WITH A POSITIVE HORIZONTAL RESECTION MARGIN (R-ESD STUDY)

Arjun D. Koch  et al.

PROSPECTIVE TRIAL EVALUATING THE SAFETY AND EFFECTIVENESS OF THE INTERSCOPE ENDOROTOR® RESECTION SYSTEM FOR DIRECT ENDOSCOPIC NECROSECTOMY OF WALLED-OF PANCREATIC NECROSIS (ENDOROTOR DEN TRIAL)
PROSPECTIVE TRIAL EVALUATING THE SAFETY AND EFFECTIVENESS OF THE INTERSCOPE ENDOROTOR® RESECTION SYSTEM FOR DIRECT ENDOSCOPIC NECROSECTOMY OF WALLED-OF PANCREATIC NECROSIS (ENDOROTOR DEN TRIAL)

Arjun D. Koch  et al.

ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)

Arjun D. Koch  et al.

ABERRANT P53 EXPRESSION IS THE STRONGEST PREDICTOR FOR NEOPLASTIC PROGRESSION IN PATIENTS WITH BARRETT’S ESOPHAGUS
ABERRANT P53 EXPRESSION IS THE STRONGEST PREDICTOR FOR NEOPLASTIC PROGRESSION IN PATIENTS WITH BARRETT’S ESOPHAGUS

Arjun D. Koch  et al.

QUALITY OF ERCP IN THE NETHERLANDS BASED ON A NATIONWIDE MANDATORY REGISTRATION
QUALITY OF ERCP IN THE NETHERLANDS BASED ON A NATIONWIDE MANDATORY REGISTRATION

Arjun D. Koch  et al.

ENDOSCOPIC RESECTION IN SUBEPITHELIAL LESIONS; EXPERIENCE OF A TERTIARY REFERRAL HOSPITAL IN THE NETHERLANDS
ENDOSCOPIC RESECTION IN SUBEPITHELIAL LESIONS; EXPERIENCE OF A TERTIARY REFERRAL HOSPITAL IN THE NETHERLANDS

Arjun D. Koch  et al.

LONG-TERM PROGNOSIS OF WESTERN PATIENTS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY ESOPHAGEAL SQUAMOUS CELL CARCINOMA IS LIMITED DUE TO COMPETING MORTALITY
LONG-TERM PROGNOSIS OF WESTERN PATIENTS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY ESOPHAGEAL SQUAMOUS CELL CARCINOMA IS LIMITED DUE TO COMPETING MORTALITY

Arjun D. Koch  et al.

INCREASED RISK OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN PATIENTS WITH SQUAMOUS DYSPLASIA: A NATIONWIDE COHORT STUDY IN THE NETHERLANDS
INCREASED RISK OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN PATIENTS WITH SQUAMOUS DYSPLASIA: A NATIONWIDE COHORT STUDY IN THE NETHERLANDS

Arjun D. Koch  et al.

ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: EARLY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: EARLY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)

Arjun D. Koch  et al.

ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK MUCOSAL ADENOCARCINOMA AND LOW- AND HIGH-RISK SUBMUCOSAL ADENOCARCINOMA ARISING IN BARRETT'S ESOPHAGUS, RESULTS OF 120 PATIENTS FROM THE DUTCH BARRETT EXPERT CENTER COHORT
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK MUCOSAL ADENOCARCINOMA AND LOW- AND HIGH-RISK SUBMUCOSAL ADENOCARCINOMA ARISING IN BARRETT'S ESOPHAGUS, RESULTS OF 120 PATIENTS FROM THE DUTCH BARRETT EXPERT CENTER COHORT

Arjun D. Koch  et al.

POOR HEALING AND POOR SQUAMOUS REGENERATION AFTER RADIOFREQUENCY ABLATION THERAPY FOR EARLY BARRETT'S NEOPLASIA: INCIDENCE, RISK FACTORS, AND OUTCOMES
POOR HEALING AND POOR SQUAMOUS REGENERATION AFTER RADIOFREQUENCY ABLATION THERAPY FOR EARLY BARRETT'S NEOPLASIA: INCIDENCE, RISK FACTORS, AND OUTCOMES

Arjun D. Koch  et al.

RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?
RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?

Arjun D. Koch  et al.

ENDOSCOPIC REASSESSMENT OF CT2N0M0 ESOPHAGEAL ADENOCARCINOMA LEADS TO DOWNSTAGING TO T1 TUMORS AND PREVENTS UNNECESSARY ADJUVANT TREATMENT: A MULTICENTER PROSPECTIVE COHORT STUDY
ENDOSCOPIC REASSESSMENT OF CT2N0M0 ESOPHAGEAL ADENOCARCINOMA LEADS TO DOWNSTAGING TO T1 TUMORS AND PREVENTS UNNECESSARY ADJUVANT TREATMENT: A MULTICENTER PROSPECTIVE COHORT STUDY

Arjun D. Koch  et al.

THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES
THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES

Arjun D. Koch  et al.

HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS
HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS

Arjun D. Koch  et al.

PREDICTION OF MORTALITY CAUSED BY OTHER CAUSES THAN ESOPHAGEAL ADENOCARCINOMA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA USING THE CHARLSON COMORBIDITY INDEX
PREDICTION OF MORTALITY CAUSED BY OTHER CAUSES THAN ESOPHAGEAL ADENOCARCINOMA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA USING THE CHARLSON COMORBIDITY INDEX

Arjun D. Koch  et al.

SCREENING FOR METACHRONOUS ESOPHAGEAL SECOND PRIMARY TUMORS IN PATIENTS WITH HEAD AND NECK CANCER
SCREENING FOR METACHRONOUS ESOPHAGEAL SECOND PRIMARY TUMORS IN PATIENTS WITH HEAD AND NECK CANCER

Arjun D. Koch  et al.

SCREENING FOR SYNCHRONOUS SECOND PRIMARY ESOPHAGEAL TUMOR IN PATIENTS WITH HEAD AND NECK CANCER
SCREENING FOR SYNCHRONOUS SECOND PRIMARY ESOPHAGEAL TUMOR IN PATIENTS WITH HEAD AND NECK CANCER

Arjun D. Koch  et al.

ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES

Arjun D. Koch  et al.

Item 1 - 20 / 21
1
2